TY - JOUR T1 - Endobronchial valve treatment for cavitary pulmonary diseases caused by non-tuberculosis mycobacteria JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA4586 VL - 54 IS - suppl 63 SP - PA4586 AU - Anastasiia Russkikh AU - Alexandra Gracheva AU - Olga Lovacheva AU - Irina Vasilyeva Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA4586.abstract N2 - Introduction: Failures in the treatment of non-tuberculous mycobacterial pulmonary diseases (NTM-PD) are often associated with the long-term treatment and intolerance of drug therapy regimens by patients, all of which require the development of new alternative treatments.Objective of Study: Define possibility of application endobronchial valves (EBV) for the treatment of cavitary NTM-PD in patients with intolerance of antibacterial therapy.Materials and Methods: 5 patients (male - 3, female - 2) with cavitary NTM-PD at whom antibacterial therapy (ABT) was discontinued due to intolerance after less than 14 days. Then installation of EBV (MedLung, Russia) was performed through fibrobronchoscopy (FBS), but ABT therapy hasn’t been resumed. All patients were urban residents, their mean age was 38,2 years. 3 patients had a unilateral, 2- bilateral. The largest cavity was 31 х 44 mm. No complications occurred during EBV application.The growth of the non-tuberculosis mycobacteria (NTMB) was obtained from sputum or bronchoalveolar lavage (BL) liquid at the solid media. Species of NTMB were identified using DNA-strips (Hain Lifescience). M. avium was identified in 2 cases, M. xenopi -1, M. chelonae -1, M. kansasii -1.Results: Duration of EBV treatment was 8-13 months, then EBV was removed with FBS. Resorption of infiltrates during period of the treatment occurred in all of patients (100 %), cavity closures were recorded in 4/5 (80%) cases. One patient had remaining thin-walled cavity. NTMB in sputum or BL fluid samples were not detected by any method.Conclusion: EBV treatment can be used successfully for closure of the cavities in NTM-PD, even if it isimpossible to carry out drug therapy.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4586.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -